Repros Therapeutics Inc. (RPRX) Sees Large Volume Increase
Repros Therapeutics Inc. (NASDAQ:RPRX) saw unusually-strong trading volume on Monday . Approximately 750,353 shares traded hands during trading, an increase of 56% from the previous session’s volume of 479,489 shares.The stock last traded at $2.40 and had previously closed at $2.21.
Separately, Zacks Investment Research downgraded Repros Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, July 13th. One equities research analyst has rated the stock with a sell rating and four have issued a hold rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $2.00.
The firm’s market cap is $55.45 million. The stock has a 50 day moving average of $1.85 and a 200-day moving average of $1.61.
Repros Therapeutics (NASDAQ:RPRX) last posted its quarterly earnings data on Tuesday, August 9th. The company reported ($0.18) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.20) by $0.02. Analysts anticipate that Repros Therapeutics Inc. will post ($0.70) earnings per share for the current fiscal year.
Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include Androxal and Proellex. The Company’s primary product candidate Androxal is a single isomer of clomiphene citrate and an orally active proprietary small molecule compound, which is developed for the treatment of secondary hypogonadism in overweight men.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.